Atlas Trials

Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines

Clinical trial NCT05150834 · UNKNOWN

Trial details

NCT number
NCT05150834
Sponsor
Korea University Guro Hospital
Status
UNKNOWN
Study type
OBSERVATIONAL
MicrobiomeVaccineCovid-19SARS-CoV-2Immunogenicity
Start date
2021-02-25
Primary completion
2021-07-16
Enrollment
53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.